STOCK TITAN

Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announces the release of its financial results for Q2 2022 on August 9, 2022, after market close. A conference call will follow at 4:30 PM EDT. The company focuses on developing infectious disease vaccines and treatments for rare liver and respiratory diseases using its proprietary mRNA technologies. Notable collaborations include partnerships with Janssen Pharmaceuticals and Ultragenyx Pharmaceutical. For more information, visit www.ArcturusRx.com.

Positive
  • None.
Negative
  • None.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm Eastern Daylight Time on August 9, 2022.

Tuesday, August 9, 2022 @ 4:30 pm EDT
Domestic: 1-800-263-0877
International: 1-323-794-2094
Conference ID: 8017918
Webcast: Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virusArcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. addition, please connect with us on Twitter and LinkedIn. For more information visit www.ArcturusRx.com.

IR and Media Contacts

Arcturus Therapeutics

IR@arcturusrx.com

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When will Arcturus Therapeutics release its financial results?

Arcturus Therapeutics will release its financial results for Q2 2022 on August 9, 2022.

What time is the Arcturus Therapeutics conference call?

The conference call is scheduled for 4:30 PM EDT on August 9, 2022.

What is the stock symbol for Arcturus Therapeutics?

The stock symbol for Arcturus Therapeutics is ARCT.

What is Arcturus Therapeutics focused on?

Arcturus Therapeutics is focused on developing mRNA medicines for infectious diseases and rare diseases.

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

ARCT Rankings

ARCT Latest News

ARCT Stock Data

462.65M
24.80M
8.46%
90.21%
16.91%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO